ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 91 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MU[yOVAhdk4EoB?= MknaO|IhcA>? Ml3GSG1UVw>? NYThNFRQ[2G3c3XkJFk4LSCub4PzJI9nKH[rYXLpcIl1gSCrbjDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEKFTE[gd4lTVkF? MUOyOlY2PzJ6OB?=
KG1a M2OxdGNmdGxiVnnhZoltcXS7IFHzd4F6 M3jx[lAuOTBizszN MV:yOEBp MWTEUXNQ MVnJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYXTOHEzOjZ3NUK3NVI>
Kasumi-1 NGDSeoFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYWwMVExKM7:TR?= MnfuNlQhcA>? NVTneZZtTE2VTx?= M3jrbGlEPTB;ND64O{DPxE1uIHTlZ5Jm[XOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHnHcJkzPjV3MkexNi=>
KG1a NGnWNGhCeG:ydH;zbZMhSXO|YYm= Mmf2NE0yOCEQvF2= MXqyOEBp NFnCN3lFVVOR M1\u[Ilv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXrzcHhbOjZ3NUK3NVI>
Kasumi-1 Mm\uRZBweHSxc3nzJGF{e2G7 NXXUXYNpOC1zMDFOwG0> NECzNI8zPCCq MlfZSG1UVw>? MWfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXvtOmdqOjZ3NUK3NVI>
MC-3  M3fFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[1M|ExNzJyIN88US=> MoPvNlQhcA>? Mn\ISG1UVw>? Ml3ZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH7SXWozPjR2N{[xOS=>
HN22  M{LnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSyMlUwPy53L{KyMlUh|ryP Mm\rNlQhcA>? M4i3bWROW09? NXvBdYVucW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlTKNlY1PDd4MUW=
MC-3  MmHZRZBweHSxc3nzJGF{e2G7 MkLCOU8yOC9{MDFOwG0> NXHPblYxOjRiaB?= NYmzbXlsTE2VTx?= NX:3V5ZCcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MojPNlY1PDd4MUW=
HN22  MWjBdI9xfG:|aYOgRZN{[Xl? M1rGclIvPS95LkWvNlIvPSEQvF2= NYC3bm54OjRiaB?= M3PZ[2ROW09? MnjVbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= M{HkSVI3PDR5NkG1
MOLT-4 NVPYO29JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2zZZZUOTBvNUCwNEBvVQ>? NYTvSnpzPzJiaB?= NXe4N3N3TE2VTx?= M1f6d2lEPTB;MD6xPVgh|ryP NXTUWXY5OjZ|OUKzN|I>
RS4;11 NHnDcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JeFFqOTBvNUCwNEBvVQ>? MmHLO|IhcA>? MVzEUXNQ MnzGTWM2OD1yLkCwNkDPxE1? M1rj[lI3Ozl{M{Oy
JURKAT NVXobVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D5VVExNTVyMECgcm0> MYm3NkBp M{jhZWROW09? M1LZPGlEPTB;Nk[g{txO M17OdlI3Ozl{M{Oy
CEM R Ml;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;kNVAuPTByMDDuUS=> NFvZVGo4OiCq NHXoe3VFVVOR NUjRRoNCUUN3ME21MlQh|ryP MVuyOlM6OjN|Mh?=
CEM S M2Ky[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLQZoUyOC13MECwJI5O M{HVRlczKGh? NI\nUnJFVVOR NF7vZmRKSzVyPUGyMlEh|ryP M{fs[|I3Ozl{M{Oy
MOLT-4 MV3BdI9xfG:|aYOgRZN{[Xl? NY\Kb2c1OTBvMUCwNEBvVQ>? MmLpNlQhcA>? NUHTVo8{TE2VTx?= NV6ydJI3[2G3c3XzJJRp\SClbHXheoFo\SCxZjDCZ4wuOiCjbnSgeIhmKGSxd37y[Yd2dGG2aX;uJI9nKEKlbD34UEBidmRiTXPsMVE> NVzGXIc1OjZ|OUKzN|I>
CEM S M4LFVmFxd3C2b4Ppd{BCe3OjeR?= MmHSNVAuOTByMDDuUS=> MkHTNlQhcA>? NU\OfXZsTE2VTx?= NH7McYJk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> MnHVNlY{QTJ|M{K=
JURKAT NEOzZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XrblExOC1zMECwJI5O M3fMUVQ5KGh? NGDBRZpFVVOR NU\kdGEyUUN3ME25OVXDuTlwMzDuUS=> NHvBR28zPjF5MkK2PS=>
LOUCY NEDmbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjJXYNsOTByLUGwNFAhdk1? MUm0PEBp MUPEUXNQ MoraTWM2OD1|Mj64xtEyOC57IH7N NHfY[FgzPjF5MkK2PS=>
WM-115 M3LBd2NmdGxiVnnhZoltcXS7IFHzd4F6 NFjMfmcyODEEoH7N M2jpSVczKGh? M4q5fYVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi MWWyOlEyPjd5Nh?=
B16 MoTXR4VtdCCYaXHibYxqfHliQYPzZZk> NGj2b48yODEEoH7N M1fUbVczKGh? NYHpNIVM\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= MXWyOlEyPjd5Nh?=
HL-60  M2HxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3HV2x2PzJiaB?= M4DkRWlEPTEEoE2gNVAvPyCwTR?= NXPlO|c3OjZyNEW2NFk>
MOLM-13  NIK1WllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHnO|IhcA>? NYfHfGlsUUN3MNMgQUAzPy57IH7N NH[yT3gzPjB2NU[wPS=>
OCI-AML3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUe3NkBp MVrJR|UxyqB;IEG5OVAhdk1? MV:yOlA1PTZyOR?=
BCWM.1 MUjBdI9xfG:|aYOgRZN{[Xl? MUOwMVEvPiEQvF2= M4n5UVI1KGh? M2LBbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUj0SppJOjV6OUOyPVA>
MWCL-1 NGjnOYxCeG:ydH;zbZMhSXO|YYm= NITlTW4xNTFwNjFOwG0> NXHicnJ1OjRiaB?= M4jmU4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NHj5engzPTh7M{K5NC=>
MM.1s NFjadZRCeG:ydH;zbZMhSXO|YYm= NH3o[nQxNTFwNjFOwG0> NEfkOpUzPCCq M2TJUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIPXXWEzPTh7M{K5NC=>
HCT116 Mom2SpVv[3Srb36gRZN{[Xl? NWT6NpVbOy9zMDFOwG0> MXqxNuKhcMLi MV7EUXNQ MmL4bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w MY[yOVcyPTB{OB?=
HCT116 BAX BAK1 DKO MUDGeY5kfGmxbjDBd5NigQ>? NYS5[WpwOy9zMDFOwG0> M3;VWlEzyqCqwrC= NXXYcXJkTE2VTx?= MnTabY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w NX;T[3ZLOjV5MUWwNlg>
HCT116 NUCzfJNpTnWwY4Tpc44hSXO|YYm= M{TlWVExKM7:TR?= NUTXOnV5OTMEoHlCpC=> NU\VeJpsTE2VTx?= M3vUTolv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= MWSyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO MlrMSpVv[3Srb36gRZN{[Xl? NFS4NmIyOCEQvF2= MYCxNuKhcMLi M{DpcmROW09? MlPtbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?= NWTDTnBSOjV5MUWwNlg>
HCT116 NXvEN2tJSXW2b4DoZYd6KEG|c3H5 MUGxNEDPxE1? MoXiNVLDqGkEoB?= NVPGRmlGTE2VTx?= MXHpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> NXXSNYVZOjV5MUWwNlg>
HCT116 BAX BAK1 DKO MXPBeZRweGijZ4mgRZN{[Xl? NXrBS5M5OTBizszN MXixNuKhcMLi NF\UdJBFVVOR NFniPYxqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? NFXHU5IzPTdzNUCyPC=>
U937 M1\YNWFxd3C2b4Ppd{BCe3OjeR?= NX3lNWE2OC5zMkWtNkDPxE1? M1rSXFI1KGh? NVrHSYxy\W6qYX7j[ZMhTEiDL2itNVEucW6mdXPl[EBieG:ydH;zbZM> NV2xfoxsOjV5MUSwNlQ>
U937  M33hZ2Fxd3C2b4Ppd{BCe3OjeR?= MVGwMlUh|ryP NFPuNnYzPCCq NUnQcHZK\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEBidmRiY3HzdIF{\S1|IHHzJJdmdGxiYYOgUo95[SCuZY\lcC=> MnXnNlU4OTRyMkS=
HL-60 AAA-Bcl-2 MlPlRZBweHSxc3nzJGF{e2G7 MWmwMVUh|ryP MUK0PEBp MlPYTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3zVcFI2PzFzNE[w
HL-60 EEE-Bcl-2 NUXZVlZUSXCxcITvd4l{KEG|c3H5 M4f4Z|AuPSEQvF2= NEOwdIE1QCCq MkS0TWM2OD13IN88cg+9lCCrbnT1Z4V{KGOnbHygZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3zMOlI2PzFzNE[w
U87 M1TYWWZ2dmO2aX;uJGF{e2G7 NUjFcpRTPTBizszN MmPYNlQhcA>? MnHGdoVlfWOnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBOVVBvMjygUW1RNTF2IHHu[EBD[2xvMh?= NFruVVgzPTZ4N{[2Ny=>
K562 MmfSR4VtdCCYaXHibYxqfHliQYPzZZk> NEX4WWcyNTFyIN88US=> NILDbm01QCCq MkPhSG1UVw>? NYH1UZI{UUN3ME2yOk44KM7:TR?= NFHheXYzPTV7NkW2NS=>
K562/Mcl -1-IRESBim M4Sw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fjV2lEPTB;OT6zJO69VQ>? M4LSfVI2PTN3OUCw
K562/Bcl- 2-IRESBim NIHFe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwM{Wg{txO MX[yOVU{PTlyMB?=
Jurkat MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7VTWM2OD1yLk[2JO69VQ>? NEHYOW0zPTV|NUmwNC=>
JurkatΔBak NXXpfINpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XCNWlEPTB-NUCg{txO Mm\1NlU2OzV7MEC=
HL60/VCR M3fWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nWdGlEPTB-MUCwJO69VQ>? NUTEeVJZOjV3M{W5NFA>
Kasumi-1 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEGg{txO NHPzelQzPTV|NUmwNC=>
Kasumi-1/ABT MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXtO2NJUUN3ME2wMlUyKM7:TR?= NUDtfI9jOjV3M{W5NFA>
THP-1 NXWydHZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTFwMkeg{txO NHq2WXEzPTV|NUmwNC=>
U937 NVHBdY9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\jTWM2OD13LkK5JO69VQ>? NH\3T2gzPTV|NUmwNC=>
C1498 M37VeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\SdGpKSzVyPU[uNVMh|ryP NYrqVXdTOjV3M{W5NFA>
RPMI 8226 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHtNmdKSzVyPUCuNlUh|ryP M2\XU|I2PTN3OUCw
MM.1S M2myd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSyfYw6UUN3ME2wMlQxKM7:TR?= MWOyOVU{PTlyMB?=
NCI-H929 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLDTWM2OD1zNT6yNUDPxE1? MoDPNlU2OzV7MEC=
U266 NWHmfoJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FZY1VUUN3ME2wMlY5KM7:TR?= M{LtOFI2PTN3OUCw
MCF-7 NYDtfZRIS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HQUVUh|ryP NVz3eo8{PDhiaB?= MVXEUXNQ NVfPZ5JQ\W6qYX7j[ZMhfGinIIPlcpNqfGm4aYT5JJRwKG:{IILh[IlifGmxbh?= M3SwdVI2PDB7MUK0
MCF-7 M{TPTWFxd3C2b4Ppd{BCe3OjeR?= M{TheVUh|ryP MVy0M|I1NzR6IHi= NF\nUYlFVVOR NEfIR|BqdmO{ZXHz[ZMhfGinIHPs[YF3\WRiUFHSVC=> MUiyOVQxQTF{NB?=
MCF-7 MmO2SpVv[3Srb36gRZN{[Xl? MnLQOUDPxE1? M{HDfVI1KGh? MVTEUXNQ MlTE[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh MXmyOVQxQTF{NB?=
MDA-MB 231  M3XFbmZ2dmO2aX;uJGF{e2G7 NGPWTJo2KM7:TR?= MYCyOEBp M{G4VmROW09? NFG0SYRmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? MlXLNlU1ODlzMkS=
ZR-75-1  MmTVSpVv[3Srb36gRZN{[Xl? MlTrOUDPxE1? NVzwZXBVOjRiaB?= Mo\1SG1UVw>? MlzZ[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NYLZZpBnOjV2MEmxNlQ>
A549 M1LTbmNmdGxiVnnhZoltcXS7IFHzd4F6 M3uzOVAuOjBizszN NFfBXIM4OiCq MmD0SG1UVw>? M4TqdYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? MmPrNlU{QDh5NkK=
H1299 NFfSNW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIrZ[JExNTJyIN88US=> NEHVfoc4OiCq NXjS[3p7TE2VTx?= M{XxdIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NUL0R4xQOjV|OEi3OlI>
HO-8910 NFPROWtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2TxfFAuOjBizszN NV7nUpo2PzJiaB?= MUfEUXNQ Mljp[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? M3vaRVI2Ozh6N{[y
HT-29 NFroVo5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkTZNE0zOCEQvF2= Ml7pO|IhcA>? Ml;YSG1UVw>? NGPHTWll\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MXSyOVM5QDd4Mh?=
HCT-116 MnHQR4VtdCCYaXHibYxqfHliQYPzZZk> MYOwMVIxKM7:TR?= NHXyOpo4OiCq NYfNeXZRTE2VTx?= Mm\O[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NUjSN2F{OjV|OEi3OlI>
A549 NH3FUI5CeG:ydH;zbZMhSXO|YYm= Mk\TNlAh|ryP MXS0PEBp MYLEUXNQ NFzhR3pqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> MXKyOVM5QDd4Mh?=
H1299 MmTSRZBweHSxc3nzJGF{e2G7 NFPk[JAzOCEQvF2= NXXqS4YzPDhiaB?= NYe4eXNoTE2VTx?= Ml2wbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJIF{eGm{aX6= NEjJNFgzPTN6OEe2Ni=>
Sc-1 M2LONWNmdGxiVnnhZoltcXS7IFHzd4F6 MkfJNE4xODBzLUGg{txO Mnj4PVYhcA>? M37JdYRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{ewc|I2Ozd|NUC4
OcI-LY18 NF3xcFhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn\DNE4xODBzLUGg{txO NGHSTFc6PiCq NYHQ[ppq\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVfKdGI3OjV|N{O1NFg>
RL  NUT3fFlQS2WubDDWbYFjcWyrdImgRZN{[Xl? NHPmbnExNjByMEGtNUDPxE1? NXnTbJFsQTZiaB?= M1LNWIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1PIeFI2Ozd|NUC4
RKO NG\E[Y1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVqwMVExKM7:TR?= NFfBUJIzPOLCiXlCpC=> NHLiV5NFVVOR M37Ob2lEPTB-4pEJNlXjiIoEtV2= MVmyOVMxPDN6Mx?=
Caco-2 NV;nS2F4S2WubDDWbYFjcWyrdImgRZN{[Xl? Ml[3NE0yOCEQvF2= NXWzRodHOjUkgJnoxsA> MnHRSG1UVw>? NVrTZ25iUUN3ME2xPU446oDLwsXN M{nYTFI2OzB2M{iz
DLD1 NWnFeXlmS2WubDDWbYFjcWyrdImgRZN{[Xl? MXqwMVExKM7:TR?= M3\Oc|I16oDLaNMg MoHzSG1UVw>? NHO0NINKSzVyPUG4Mlc56oDLwsXN Mn7uNlU{ODR|OEO=
LS411N Mlq2R4VtdCCYaXHibYxqfHliQYPzZZk> NHmwfJYxNTFyIN88US=> M361ZVI16oDLaNMg M2fteWROW09? M2TzZWlEPTB;MUGuOFfjiIoEtV2= NVTNdoZGOjV|MESzPFM>
SW620 MnXCR4VtdCCYaXHibYxqfHliQYPzZZk> NFzNbFkxNTFyIN88US=> M2juSlI16oDLaNMg MmjwSG1UVw>? M3n1OGlEPTB;MUKuNlTjiIoEtV2= Mk\BNlU{ODR|OEO=
HCT116 Mn72R4VtdCCYaXHibYxqfHliQYPzZZk> NInufIQxNTFyIN88US=> M2XB[VI16oDLaNMg MX;EUXNQ M4LBVmlEPTB;MkCuOFnjiIoEtV2= NH7LXXEzPTNyNEO4Ny=>
HaCaT NELmSpVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1S5VlAvOS9zL{GwJO69VQ>? Mn;LNlQhcA>? NUfD[|RGTE2VTx?= NEjqbWZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVrUZ5ZnOjV{MUC3PVU>
A5-RT3 NGrPfYJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3P2U|AvOS9zL{GwJO69VQ>? MU[yOEBp Mm\PSG1UVw>? M1PwSoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHPpcHgzPTJzMEe5OS=>
HaCaT MXTGeY5kfGmxbjDBd5NigQ>? MkXzNVDjiIoQvF2= MUiyOE81QCCq MWrEUXNQ MmPSbY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w NH31VlAzPTJzMEe5OS=>
A5-RT3 MorrSpVv[3Srb36gRZN{[Xl? NH;tN3QyOOLCid88US=> MkXMNlQwPDhiaB?= MWrEUXNQ M37ndolv\HWlZYOgUW1RKGGwZDDEUmEh\nKjZ33lcpRifGmxbh?= Ml7TNlUzOTB5OUW=
A5-RT3 M3zRbWZ2dmO2aX;uJGF{e2G7 MlfLOUDPxE1? MmTDOkBp MY\EUXNQ MXPpcoR2[2W|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy NUTLSnZWOjV{MUC3PVU>
U266 NH;UTotHfW6ldHnvckBCe3OjeR?= MWW1NFAwPzVyIH7N NEj4bnYzPC92ODDo M3L3TGROW09? NFvZdodld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> M2PoR|I2OjB6OEi4
RPMI8226 Mnj0SpVv[3Srb36gRZN{[Xl? MnXaOVAxNzd3MDDuUS=> M2TsXlI1NzR6IHi= MlfqSG1UVw>? MXPkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M{O5b|I2OjB6OEi4
MM.1S MUXGeY5kfGmxbjDBd5NigQ>? M2TOOFUxOC95NUCgcm0> MV2yOE81QCCq NIThPIhFVVOR MoH1[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt NWH1dFBuOjV{MEi4PFg>
Clone A NITVVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:yUVAvOuLCk{[wJO69VQ>? MWe3NkBp M2izbmROW09? NHrVV25KSzVyPUeuOUDPxE1? MUOyOVIxQDh6Mh?=
CX-1 NW\z[41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi5T412OC5{4pETOlAh|ryP NHHCeZY4OiCq Mn34SG1UVw>? MoTRTWM2OD1zLkig{txO MWeyOVIxQDh6Mh?=
LS174T M3n6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rvWFAvOuLCk{[wJO69VQ>? MVu3NkBp M1XJWGROW09? NEjhV4ZKSzVyPUG4MlMh|ryP M3iyfVI2OjB6OEiy
HT29 MnT0RZBweHSxc3nzJGF{e2G7 MWCxM|UwOTBizszN NHXpTHY1QCCq M1fjcYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3vjVFI2OTl{MUi4
SW480 MlLiRZBweHSxc3nzJGF{e2G7 NUXPcJVUOS93L{GwJO69VQ>? MWi0PEBp MW\jZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFzDcnYzPTF7MkG4PC=>
Colo205 NY\ZblZ7SXCxcITvd4l{KEG|c3H5 NUT5bZJHOS93L{GwJO69VQ>? MWe0PEBp MUTjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NInURVMzPTF7MkG4PC=>
Caco2 M{jyc2Fxd3C2b4Ppd{BCe3OjeR?= NF2yTY8yNzVxMUCg{txO M132OFQ5KGh? NIPibFdk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX3iV49VOjVzOUKxPFg>
PCI-13 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp NVH1VYdlTE2VTx?= MnO1S2k2OD1zNTFCtUAyNjhizszN M4PKfVI2OTN7M{i3
PCI-15B M{\LUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp MkXNSG1UVw>? M1;3dGdKPTB;MUGgxtEhPC53IN88US=> NFL1NnEzPTF|OUO4Oy=>
UM-SCC22B MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHm[YR7PzJiaB?= MorSSG1UVw>? MoHES2k2OD1zOTFCtUAzNjlizszN M{LlO|I2OTN7M{i3
UM-SCC47 M4\FVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvGUXg1PzJiaB?= NGKxe4RFVVOR MmKzS2k2OD1zOTFCtUAyOi5|IN88US=> NWfYOW0yOjVzM{mzPFc>
93-VU-147T M2eyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzxO|IhcA>? MkSzSG1UVw>? MknkS2k2OD12LkOgxtEhOy53IN88US=> NEWwZ3YzPTF|OUO4Oy=>
UD-SCC2 M1fPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PGdVczKGh? M3y1RmROW09? Mly1S2k2OD1{ODFCtUAzNjlizszN NV3BUmxKOjVzM{mzPFc>
UPCI:SCC90 M4PVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7CVFU4OiCq MlTTSG1UVw>? Mn3xS2k2OD14Lk[gxtEhOS53IN88US=> M2m1bFI2OTN7M{i3
RPMI-8226  MoW3R4VtdCCYaXHibYxqfHliQYPzZZk> NXzDdmhEOTJ3L{K1NE82ODBibl2= NWq1PYRHPDiqwrC= MUnEUXNQ M{T0ZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2ezbVI2ODB6MkCy
OPM-2  MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXSxNlUwOjVyL{WwNEBvVQ>? NWTjSXRiPDiqwrC= M4LaOGROW09? M1riVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3vyUFI2ODB6MkCy
RPMI-8226  M4LoemFxd3C2b4Ppd{BCe3OjeR?= MYexNlUwOjVyL{WwNEBvVQ>? M{HFflQ5cMLi MnT0SG1UVw>? NFHGfHlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWnt[Yo3OjVyMEiyNFI>
OPM-2  MXjBdI9xfG:|aYOgRZN{[Xl? M1\lfFEzPS9{NUCvOVAxKG6P NW\IT4RMPDiqwrC= NYG4eG5LTE2VTx?= NWPYRYZncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1jQWVI2ODB6MkCy
COG-LL-319 MnLYSpVv[3Srb36gRZN{[Xl? MkPkNVAxKG6P NWTDNFU3OS9|L{[gbC=> NI\4epNFVVOR MojrbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? M3PKUVI1QTVzNEey
RS4;11 Mn\jSpVv[3Srb36gRZN{[Xl? MnzqNVAxKG6P NFexe3gyNzNxNjDo M{TTRmROW09? MlvKbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDNZ4wuOSClbHXheoFo\Q>? MmLaNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID